Trial reportBlood2018
A simplified scoring system in de novo follicular lymphoma treated initially with immunochemotherapy.
Trial report in Blood, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04587388 (Towards Personalized Medicine for Refractory/Relapsed Follicular Lymphoma Patients), which is not on this map. Cited by 116 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Towards Personalized Medicine for Refractory/Relapsed Follicular Lymphoma Patients: the Cantera/Lupiae Registry
Who cites it
116 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Guidelines for Diagnosis, Treatment, and Follow-Up of Patients with Follicular Lymphoma-Spanish Lymphoma Group (GELTAMO) 2025.Cancers · 2026Guideline
- Efficacy of front-line immunochemotherapy for follicular lymphoma: a network meta-analysis of randomized controlled trials.Blood cancer journal · 2022Pooled it
- Frontline acalabrutinib, lenalidomide and rituximab for advanced stage follicular lymphoma with high tumor burden: phase II trial.Nature communications · 2025Trial
- Six-month rituximab-lenalidomide regimen in advanced untreated follicular lymphoma: SAKK 35/10 trial 10-year update.Blood advances · 2025Trial
- Long-term follow-up of lenalidomide and rituximab as initial treatment of follicular lymphoma.Blood · 2021Trial
- Follicular Lymphoma Evaluation Index (FLEX): A new clinical prognostic model that is superior to existing risk scores for predicting progression-free survival and early treatment failure after frontline immunochemotherapy.American journal of hematology · 2020Trial
- An interpretable PET/CT-based radiomic-clinical model for predicting bone marrow involvement in follicular lymphoma: comparison of pelvic and spine-pelvis VOI frameworks.European journal of nuclear medicine and molecular imaging · 2026Article
- A deep learning PET/CT biomarker for early progression (POD24) and survival stratification in follicular lymphoma: a multicenter study.European journal of nuclear medicine and molecular imaging · 2026Article
- [The prognostic value of IGHV gene segment usage in advanced-stage follicular lymphoma with bone marrow infiltration].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2026Article
- Chemotherapy-Sparing Strategies in Follicular Lymphoma: Emerging Targeted and Immune-Based Approaches.European journal of haematology · 2026Review
- Consensus recommendations from the 2024 International Follicular Lymphoma Scientific Workshop.Blood advances · 2026Review
- Prognostic value of tumor bulk in modern management of common lymphoma subtypes: an Australasian Lymphoma and Related Diseases Registry study.Haematologica · 2026Article
- Article
- Prognostic significance of Ki-67 in grade 3A follicular lymphoma and development of a novel PFS nomogram.Annals of hematology · 2026Article
- Early prognostic stratification of follicular lymphoma through ¹⁸F-FDG PET/CT tumor metabolic parameters and clinical characteristics.EJNMMI research · 2026Article
- FLIPI24: A Modern Prognostic Model and Clinical Trial Enrichment Tool for Newly Diagnosed Follicular Lymphoma.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2026Article
- Baseline systemic immune-inflammation index and a novel FLIPI-SII model predict POD24 and long-term survival in grade 1-3a follicular lymphoma.Frontiers in immunology · 2026Article
- Review of the Management of Relapsed/Refractory Follicular Lymphoma: An Italian Perspective.Hematological oncology · 2025Review
- Clinical characteristics and molecular heterogeneity in Follicular lymphoma with extranodal involvement.Genome medicine · 2025Article
- Clinical features and prognosis analysis of patients with follicular lymphoma: a real-world study in China.Annals of hematology · 2025Article
56 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
25 authors.
Funding
Abstract
In follicular lymphoma (FL), no prognostic index has been built based solely on a cohort of patients treated with initial immunochemotherapy. There is currently a need to define parsimonious clinical models for trial stratification and to add on biomolecular factors. Here, we confirmed the validity of both the follicular lymphoma international prognostic index (FLIPI) and the FLIPI2 in the large prospective PRIMA trial cohort of 1135 patients treated with initial R-chemotherapy ± R maintenance. Furthermore, we developed a new prognostic tool comprising only 2 simple parameters (bone marrow involvement and β
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.